{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:45Z","timestamp":1792098585226,"version":"4.4.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10067-019-04745-5","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T22:02:36Z","timestamp":1565992956000},"page":"3317-3330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Raynaud\u2019s phenomenon\u2014an update on diagnosis, classification and management"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-2364","authenticated-orcid":false,"given":"John D","family":"Pauling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"4745_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417","journal-title":"Rheumatol Int"},{"key":"4745_CR2","unstructured":"Barlow T (1862 and 1874). On local asphyxia and symmetrical gangrene of the extremities, and new research on the nature and treatment of local asphyxia of the extremities. Selected monographs. London: New Sydenham Society"},{"key":"4745_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00000441-193202000-00004","volume":"183","author":"E Allen","year":"1932","unstructured":"Allen E, Brown G (1932) Raynaud\u2019s disease: a critical review of minimal requisites for diagnosis. Am J M Sc 183:187\u2013200","journal-title":"Am J M Sc"},{"key":"4745_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","volume":"48-49","author":"E Maverakis","year":"2014","unstructured":"Maverakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allanore Y, Guiducci S, Hesselstrand R, Hummers LK, Duong C, Kahaleh B, Macgregor A, Matucci-Cerinic M, Wollheim FA, Mayes MD, Gershwin ME (2014) International consensus criteria for the diagnosis of Raynaud\u2019s phenomenon. J Autoimmun 48-49:60\u201365","journal-title":"J Autoimmun"},{"key":"4745_CR5","first-page":"879","volume":"24","author":"HR Maricq","year":"1997","unstructured":"Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C et al (1997) Geographic variation in the prevalence of Raynaud\u2019s phenomenon: a 5 region comparison. J Rheumatol 24:879\u2013889","journal-title":"J Rheumatol"},{"key":"4745_CR6","first-page":"485","volume":"10","author":"EC LeRoy","year":"1992","unstructured":"LeRoy EC, Medsger TA (1992) Raynaud\u2019s phenomenon: a proposal for classification. Clin Exp Rheumatol 10:485\u2013488","journal-title":"Clin Exp Rheumatol"},{"key":"4745_CR7","doi-asserted-by":"crossref","unstructured":"Brennan P, Silman A, Black C, Bernstein R, Coppock J, Maddison P, et al. (1993) Validity and reliability of three methods used in the diagnosis of Raynaud\u2019s phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 32:357\u2013361","DOI":"10.1093\/rheumatology\/32.5.357"},{"key":"4745_CR8","doi-asserted-by":"publisher","first-page":"e006389","DOI":"10.1136\/bmjopen-2014-006389","volume":"5","author":"R Garner","year":"2015","unstructured":"Garner R, Kumari R, Lanyon P, Doherty M, Zhang W (2015) Prevalence, risk factors and associations of primary Raynaud\u2019s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open 5:e006389\u2013e006389","journal-title":"BMJ Open"},{"key":"4745_CR9","first-page":"403","volume":"128","author":"J Hutchinson","year":"1901","unstructured":"Hutchinson J (1901) Raynaud\u2019s phenomenon. Med Press Circ 128:403\u2013405","journal-title":"Med Press Circ"},{"key":"4745_CR10","first-page":"2291","volume":"25","author":"N Hadler","year":"1998","unstructured":"Hadler N (1998) \u201cPrimary Raynaud\u2019s\u201d is not a disease or even a disorder; it\u2019s a trait. J Rheumatol 25:2291\u20132294","journal-title":"J Rheumatol"},{"key":"4745_CR11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1001\/jama.1932.02740700012003","volume":"99","author":"E Allen","year":"1932","unstructured":"Allen E, Brown G (1932) Raynaud\u2019s disease: a clinical study of one hundred and forty-seven cases. J Am Med Assoc 99:1472\u20131478","journal-title":"J Am Med Assoc"},{"key":"4745_CR12","first-page":"741","volume":"19","author":"O Bayle","year":"1990","unstructured":"Bayle O, Consoli SM, Baudin M, Vayssairat M, Fiessinger JN, Housset E (1990) Idiopathic and secondary Raynaud\u2019s phenomenon. A comparative psychosomatic approach. Presse Med 19:741\u2013745","journal-title":"Presse Med"},{"key":"4745_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0304-3959(88)90019-X","volume":"32","author":"H Vaer\u00f8y","year":"1998","unstructured":"Vaer\u00f8y H, Helle R, F\u00f8rre O, K\u00e5ss E, Terenius L (1998) Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32:21\u201326","journal-title":"Pain"},{"key":"4745_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3899\/jrheum.080212","volume":"36","author":"F Wolfe","year":"2009","unstructured":"Wolfe F, Petri M, Alarcon G, Goldman J, Chakravarty E, Katz R et al (2009) Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 36:82\u201388","journal-title":"J Rheumatol"},{"key":"4745_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00296-016-3483-6","volume":"36","author":"M Scolnik","year":"2016","unstructured":"Scolnik M, Vasta B, Hart DJ, Shipley JA, McHugh NJ, Pauling JD (2016) Symptoms of Raynaud\u2019s phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology. Rheumatol Int 36:1371\u20131377","journal-title":"Rheumatol Int"},{"key":"4745_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/CLEP.S75482","volume":"7","author":"PJ Nietert","year":"2015","unstructured":"Nietert PJ, Shaftman SR, Silver RM, Wolf BJ, Egan BM, Hunt KJ, Smith EA (2015) Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. Clin Epidemiol 7:161\u2013168","journal-title":"Clin Epidemiol"},{"key":"4745_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s10067-016-3442-3","volume":"36","author":"C Pizzorni","year":"2017","unstructured":"Pizzorni C, Sulli A, Smith V, Ruaro B, Trombetta AC, Cutolo M, Paolino S (2017) Primary Raynaud\u2019s phenomenon and nailfold videocapillaroscopy: age-related changes in capillary morphology. Clin Rheumatol 36:1637\u20131642","journal-title":"Clin Rheumatol"},{"key":"4745_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/archinte.158.6.595","volume":"158","author":"G Spencer-Green","year":"1998","unstructured":"Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158:595\u2013600","journal-title":"Arch Intern Med"},{"key":"4745_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"2007","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 2007:754\u2013763","journal-title":"Ann Rheum Dis"},{"key":"4745_CR20","first-page":"S-10","volume":"32","author":"VC Delisle","year":"2014","unstructured":"Delisle VC, Hudson M, Baron M, Thombs BD, And The Canadian Scleroderma Research Group A (2014) Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry. Clin Exp Rheumatol 32:S-10\u2013S-14","journal-title":"Clin Exp Rheumatol"},{"key":"4745_CR21","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"M Koenig","year":"2008","unstructured":"Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich \u00c9, Grodzicky T, Raymond Y, Sen\u00e9cal JL (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58:3902\u20133912","journal-title":"Arthritis Rheum"},{"key":"4745_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/rheumatology\/kes315","volume":"52","author":"D Schneeberger","year":"2012","unstructured":"Schneeberger D, Tyndall A, Kay J, S\u00f8ndergaard KH, Carreira PE, Morgiel E et al (2012) Systemic sclerosis without antinuclear antibodies or Raynaud\u2019s phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford) 52:560\u2013567","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","volume":"72","author":"DF Fiorentino","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J Am Acad Dermatol 72:449\u2013455","journal-title":"J Am Acad Dermatol"},{"key":"4745_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/0961203315575586","volume":"24","author":"MF Carpintero","year":"2015","unstructured":"Carpintero MF, Martinez L, Fernandez I, Romero ACG, Mejia C, Zang YJ, Hoffman RW, Greidinger EL (2015) Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus 24:1057\u20131066","journal-title":"Lupus"},{"key":"4745_CR25","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s10067-015-2941-y","volume":"34","author":"M Arroyo-\u00c1vila","year":"2015","unstructured":"Arroyo-\u00c1vila M, Santiago-Casas Y, McGwin G, Cantor RS, Petri M, Ramsey-Goldman R, Reveille JD, Kimberly RP, Alarc\u00f3n GS, Vil\u00e1 LM, Brown EE (2015) Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin Rheumatol 34:1217\u20131223","journal-title":"Clin Rheumatol"},{"key":"4745_CR26","first-page":"1403","volume":"27","author":"M Nakano","year":"2000","unstructured":"Nakano M, Ohuchi Y, Hasegawa H, Kuroda T, Ito S, Gejyo F (2000) Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol 27:1403\u20131407","journal-title":"J Rheumatol"},{"key":"4745_CR27","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.1038\/s41598-017-07137-4","volume":"7","author":"N Kuramoto","year":"2017","unstructured":"Kuramoto N, Ohmura K, Ikari K, Yano K, Furu M, Yamakawa N, Hashimoto M, Ito H, Fujii T, Murakami K, Nakashima R, Imura Y, Yukawa N, Yoshifuji H, Taniguchi A, Momohara S, Yamanaka H, Matsuda F, Mimori T, Terao C (2017) Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis. Sci Rep 7:6911","journal-title":"Sci Rep"},{"key":"4745_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/1756-185X.12684","volume":"18","author":"K-E Lee","year":"2015","unstructured":"Lee K-E, Kang J-H, Lee J-W, Wen L, Park D-J, Kim T-J, Park YW, Lee SS (2015) Anti-centromere antibody-positive Sj\u00f6gren\u2019s syndrome: a distinct clinical subgroup? Int J Rheum Dis 18:776\u2013782","journal-title":"Int J Rheum Dis"},{"key":"4745_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40744-018-0126-2","volume":"5","author":"M Tsukamoto","year":"2018","unstructured":"Tsukamoto M, Suzuki K, Takeuchi T (2018) Clinical and immunological features of anti-centromere antibody-positive primary Sj\u00f6gren\u2019s syndrome. Rheumatol Ther 5:499\u2013505","journal-title":"Rheumatol Ther"},{"key":"4745_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/ard.56.4.230","volume":"56","author":"M Hebbar","year":"1997","unstructured":"Hebbar M, Lassalle P, Delneste Y, Hatron PY, Devulder B, Tonnel AB, Janin A (1997) Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 56:230\u2013234","journal-title":"Ann Rheum Dis"},{"key":"4745_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1001-9294(10)60016-8","volume":"25","author":"M-T Li","year":"2010","unstructured":"Li M-T, Ai J, Tian Z, Fang Q, Zheng W-J, Zeng X-J, Zeng XF (2010) Prevalence of anti-endothelial cell antibodies in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chin Med Sci J 25:27\u201331","journal-title":"Chin Med Sci J"},{"key":"4745_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/ard.2010.135772","volume":"70","author":"G Riemekasten","year":"2011","unstructured":"Riemekasten G, Philippe A, N\u00e4ther M, Slowinski T, M\u00fcller DN, Heidecke H et al (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70:530\u2013536","journal-title":"Ann Rheum Dis"},{"key":"4745_CR33","first-page":"S123","volume":"33","author":"AA Shah","year":"2015","unstructured":"Shah AA, Montagne J, Oh S-Y, Wigley FM, Casciola-Rosen L (2015) Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma. Clin Exp Rheumatol 33:S123\u2013S126","journal-title":"Clin Exp Rheumatol"},{"key":"4745_CR34","first-page":"454","volume":"15","author":"HR Maricq","year":"1998","unstructured":"Maricq HR, Weinrich MC (1998) Diagnosis of Raynaud\u2019s phenomenon assisted by color charts. J Rheumatol 15:454\u2013459","journal-title":"J Rheumatol"},{"key":"4745_CR35","first-page":"171","volume":"37","author":"H Wollersheim","year":"1990","unstructured":"Wollersheim H, Thien T (1990) The diagnostic value of clinical signs and symptoms in patients with Raynaud\u2019s phenomenon. A cross-sectional study. Neth J Med 37:171\u2013182","journal-title":"Neth J Med"},{"key":"4745_CR36","doi-asserted-by":"publisher","first-page":"371960","DOI":"10.1155\/2015\/371960","volume":"2015","author":"F Ingegnoli","year":"2015","unstructured":"Ingegnoli F, Gualtierotti R, Orenti A, Schioppo T, Marfia G, Campanella R et al (2015) Uniphasic blanching of the fingers, abnormal capillaroscopy in nonsymptomatic digits, and autoantibodies: expanding options to increase the level of suspicion of connective tissue diseases beyond the classification of Raynaud\u2019s phenomenon. J Immunol Res 2015:371960","journal-title":"J Immunol Res"},{"key":"4745_CR37","doi-asserted-by":"publisher","unstructured":"Pauling JD, Reilly E, Smith T, Frech TM. Evolving symptoms of Raynaud\u2019s phenomenon in systemic sclerosis are associated with physician and patient-reported assessments of disease severity. Arthritis Care Res (Hoboken) 2018. doi: https:\/\/doi.org\/10.1002\/acr.23729 .","DOI":"10.1002\/acr.23729"},{"key":"4745_CR38","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/acr.23475","volume":"70","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S (2018) A multi-national qualitative research study exploring the patient experience of Raynaud\u2019s phenomenon in systemic sclerosis. Arthritis Care Res 70:1373\u20131384","journal-title":"Arthritis Care Res"},{"key":"4745_CR39","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/art.40481","volume":"70","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Saketkoo LA, Domsic RT (2018) Patient perceptions of the Raynaud\u2019s condition score diary provide insight into its performance in clinical trials of Raynaud\u2019s phenomenon: comment on the article by Denton et al. Arthritis Rheum 70:973\u2013974","journal-title":"Arthritis Rheum"},{"key":"4745_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/rheumatology\/key026","volume":"58","author":"JD Pauling","year":"2019","unstructured":"Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D (2019) The patient experience of Raynaud\u2019s phenomenon in systemic sclerosis. Rheumatology (Oxford) 58:18\u201326","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/2397198318774307","volume":"3","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL (2018) Patient-reported outcome instruments for assessing Raynaud\u2019s phenomenon in systemic sclerosis: a SCTC vascular working group report. J Scleroderma Relat Disord 3:249\u2013252","journal-title":"J Scleroderma Relat Disord"},{"key":"4745_CR42","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.141437","volume":"42","author":"JD Pauling","year":"2015","unstructured":"Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ (2015) Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic sclerosis: a comparison using the Raynaud condition score diary. J Rheumatol 42:1163\u20131168","journal-title":"J Rheumatol"},{"key":"4745_CR43","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/art.40457","volume":"70","author":"JD Wilkinson","year":"2018","unstructured":"Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME, Britton J, Buch MH, del Galdo F, Denton CP, Dinsdale G, Griffiths B, Hall F, Howell K, MacDonald A, McHugh NJ, Manning JB, Pauling JD, Roberts C, Shipley JA, Herrick AL, Murray AK (2018) A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud\u2019s phenomenon. Arthritis Rheum 70:903\u2013911","journal-title":"Arthritis Rheum"},{"key":"4745_CR44","doi-asserted-by":"publisher","unstructured":"Pauling JD, Reilly EE, Smith T, Frech TM (2019) Factors influencing Raynaud\u2019s condition score diary outcomes in systemic sclerosis. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.180818","DOI":"10.3899\/jrheum.180818"},{"key":"4745_CR45","doi-asserted-by":"crossref","unstructured":"Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL (2015) Prediction and impact of attacks of Raynaud\u2019s phenomenon, as judged by patient perception. Rheumatol 54:1443\u20131447","DOI":"10.1093\/rheumatology\/kev002"},{"key":"4745_CR46","first-page":"1734","volume":"26","author":"HR Watson","year":"1999","unstructured":"Watson HR, Robb R, Belcher G, Belch JJ (1999) Seasonal variation of Raynaud\u2019s phenomenon secondary to systemic sclerosis. J Rheumatol 26:1734\u20131737","journal-title":"J Rheumatol"},{"key":"4745_CR47","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1136\/bmj.287.6404.1499","volume":"287","author":"RR Freedman","year":"1983","unstructured":"Freedman RR, Ianni P (1983) Role of cold and emotional stress in Raynaud\u2019s disease and scleroderma. Br Med J (Clin Res Ed) 287:1499\u20131502","journal-title":"Br Med J (Clin Res Ed)"},{"key":"4745_CR48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/03009742.2017.1350745","volume":"47","author":"G Sandqvist","year":"2018","unstructured":"Sandqvist G, Wollmer P, Scheja A, Wildt M, Hesselstrand R (2018) Raynaud\u2019s phenomenon and its impact on activities in daily life during one year of follow-up in early systemic sclerosis. Scand J Rheumatol 47:206\u2013209","journal-title":"Scand J Rheumatol"},{"key":"4745_CR49","doi-asserted-by":"crossref","unstructured":"Pauling J, Nagaraja V, Khanna D Insight into the contrasting findings of therapeutic trials of digital ischaemic manifestations of systemic sclerosis. Curr Treat Opinions in Rheum 5:85\u2013103","DOI":"10.1007\/s40674-019-00118-w"},{"key":"4745_CR50","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3899\/jrheum.091117","volume":"37","author":"B Chikura","year":"2010","unstructured":"Chikura B, Moore T, Manning J, Vail A, Herrick AL (2010) Thumb involvement in Raynaud\u2019s phenomenon as an indicator of underlying connective tissue disease. J Rheumatol 37:783\u2013786","journal-title":"J Rheumatol"},{"key":"4745_CR51","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/rheumatology\/keq310","volume":"50","author":"M Bassel","year":"2011","unstructured":"Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD (2011) Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 50:762\u2013767","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","volume":"46","author":"C Frantz","year":"2016","unstructured":"Frantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT, Connolly K, Varga J, Matucci-Cerinic M, Allanore Y (2016) Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum 46:115\u2013123","journal-title":"Semin Arthritis Rheum"},{"key":"4745_CR53","first-page":"88","volume":"36","author":"L Kwakkenbos","year":"2018","unstructured":"Kwakkenbos L, Sanchez TA, Turner KA, Mouthon L, Carrier M-E, Hudson M et al (2018) The association of sociodemographic and disease variables with hand function: a scleroderma patient-centered intervention network cohort study. Clin Exp Rheumatol 36:88\u201394","journal-title":"Clin Exp Rheumatol"},{"key":"4745_CR54","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/art.10486","volume":"46","author":"PA Merkel","year":"2002","unstructured":"Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jim\u00e9nez SA, White B, Seibold JR, Wigley FM, for the Scleroderma Clinical Trials Consortium (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon. Arthritis Rheum 46:2410\u20132420","journal-title":"Arthritis Rheum"},{"key":"4745_CR55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","volume":"8","author":"AL Herrick","year":"2012","unstructured":"Herrick AL (2012) The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 8:469\u2013479","journal-title":"Nat Rev Rheumatol"},{"key":"4745_CR56","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/art.38923","volume":"67","author":"G-A Giurgea","year":"2015","unstructured":"Giurgea G-A, Mlekusch W, Charwat-Resl S, Mueller M, Hammer A, Gschwandtner ME et al (2015) Relationship of age and body mass index to skin temperature and skin perfusion in primary Raynaud\u2019s phenomenon. Arthritis Rheumatol (Hoboken, NJ) 67:238\u2013242","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"4745_CR57","doi-asserted-by":"crossref","unstructured":"Munir S, Freidin MB, Brain S, Williams FMK (2018) Association of Raynaud\u2019s phenomenon with a polymorphism in the NOS1 gene. PLoS One 2018;13:e0196279","DOI":"10.1371\/journal.pone.0196279"},{"key":"4745_CR58","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMcp013013","volume":"347","author":"FM Wigley","year":"2002","unstructured":"Wigley FM (2002) Raynaud\u2019s phenomenon. N Engl J Med 347:1001\u20131008","journal-title":"N Engl J Med"},{"key":"4745_CR59","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1136\/annrheumdis-2018-214161","volume":"78","author":"M Hughes","year":"2019","unstructured":"Hughes M, Baker A, Farrington S, Pauling JD (2019) Patient organisation-led initiatives can play an important role in raising awareness about Raynaud\u2019s phenomenon and encourage earlier healthcare utilisation for high-risk groups. Ann Rheum Dis 78:439\u2013441","journal-title":"Ann Rheum Dis"},{"key":"4745_CR60","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/art.1780390717","volume":"39","author":"RR Freedman","year":"1996","unstructured":"Freedman RR, Mayes MD (1996) Familial aggregation of primary Raynaud\u2019s disease. Arthritis Rheum 39:1189\u20131191","journal-title":"Arthritis Rheum"},{"key":"4745_CR61","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/art.27469","volume":"62","author":"T Frech","year":"2010","unstructured":"Frech T, Khanna D, Markewitz B, Mineau G, Pimentel R, Sawitzke A (2010) Heritability of vasculopathy, autoimmune disease, and fibrosis: a population-based study of systemic sclerosis. Arthritis Rheum 62:2109\u20132116","journal-title":"Arthritis Rheum"},{"key":"4745_CR62","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","volume":"57","author":"JD Pauling","year":"2018","unstructured":"Pauling JD, Salazar G, Lu H, Betteridge ZE, Assassi S, Mayes MD, McHugh NJ (2018) Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1\/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford) 57:712\u2013717","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR63","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","volume":"54","author":"M Hughes","year":"2015","unstructured":"Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B, Baildam E, Denton CP, Herrick AL (2015) Consensus best practice pathway of the UK scleroderma study group: digital vasculopathy in systemic sclerosis. Rheumatology (Oxford) 54:2015\u20132024","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR64","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/rheumatology\/ket153","volume":"52","author":"M Cutolo","year":"2013","unstructured":"Cutolo M, Smith V (2013) State of the art on nailfold capillaroscopy: a reliable diagnostic tool and putative biomarker in rheumatology? Rheumatology (Oxford) 52:1933\u20131940","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR65","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/rheumatology\/kev441","volume":"55","author":"V Smith","year":"2016","unstructured":"Smith V, Beeckman S, Herrick AL, Decuman S, Deschepper E, De Keyser F et al (2016) An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology (Oxford) 55:883\u2013890","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/25785826.2018.1531189","volume":"4","author":"S Kubo","year":"2018","unstructured":"Kubo S, Smith V, Cutolo M, Tanaka Y (2018) The role of nailfold videocapillaroscopy in patients with systemic sclerosis. Immunol Med 4:113\u2013119","journal-title":"Immunol Med"},{"key":"4745_CR67","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.autrev.2017.11.025","volume":"7","author":"M Cutolo","year":"2018","unstructured":"Cutolo M, Melsens K, Wijnant S, Ingegnoli F, Thevissen K, De Keyser F et al (2018) Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal. Autoimmun Rev 7:344\u2013352","journal-title":"Autoimmun Rev"},{"key":"4745_CR68","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00296-015-3396-9","volume":"36","author":"H Corominas","year":"2016","unstructured":"Corominas H, Ortiz-Santamar\u00eda V, Castellv\u00ed I, Moreno M, Morl\u00e0 R, Clavaguera T et al (2016) Nailfold capillaroscopic findings in primary Sj\u00f6gren\u2019s syndrome with and without Raynaud\u2019s phenomenon and\/or positive anti-SSA\/Ro and anti-SSB\/La antibodies. Rheumatol Int 36:365\u2013369","journal-title":"Rheumatol Int"},{"key":"4745_CR69","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/rheumatology\/35.11.1127","volume":"35","author":"M Bukhari","year":"1996","unstructured":"Bukhari M, Herrick AL, Moore T, Manning J, Jayson MI (1996) Increased nailfold capillary dimensions in primary Raynaud\u2019s phenomenon and systemic sclerosis. Br J Rheumatol 35:1127\u20131131","journal-title":"Br J Rheumatol"},{"key":"4745_CR70","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3899\/jrheum.180355","volume":"46","author":"M Sebastiani","year":"2019","unstructured":"Sebastiani M, Triantafyllias K, Manfredi A, Gonz\u00e1lez-Gay MA, Palmou-Fontana N, Cassone G, Drott U, Delbr\u00fcck C, Rojas-Serrano J, Bertolazzi C, Nu\u00f1o L, Giannini M, Iannone F, Vicente EF, Casta\u00f1eda S, Selva-O\u2019Callaghan A, Trallero Araguas E, Emmi G, Iuliano A, Bauhammer J, Miehle N, Parisi S, Cavagna L, Codullo V, Montecucco C, Lopez-Longo FJ, Mart\u00ednez-Barrio J, Nieto-Gonz\u00e1lez JC, Vichi S, Confalonieri M, Tomietto P, Bergner R, Sulli A, Bonella F, Furini F, Scir\u00e8 CA, Bortoluzzi A, Specker C, Barsotti S, Neri R, Mosca M, Caproni M, Weinmann-Menke J, Schwarting A, Smith V, Cutolo M, The American and European Network of Antisynthetase Syndrome Collaborative Group (2019) Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: results of a multicenter international study. J Rheumatol 46:279\u2013284","journal-title":"J Rheumatol"},{"key":"4745_CR71","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/rheumatology\/keu533","volume":"54","author":"M Hughes","year":"2015","unstructured":"Hughes M, Moore T, O\u2019Leary N, Tracey A, Ennis H, Dinsdale G, Murray A, Roberts C, Herrick AL (2015) A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders. Rheumatol 54:1435\u20131442","journal-title":"Rheumatol"},{"key":"4745_CR72","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.mvr.2011.03.007","volume":"82","author":"JD Pauling","year":"2011","unstructured":"Pauling JD, Flower V, Shipley JA, Harris ND, McHugh NJ (2011) Influence of the cold challenge on the discriminatory capacity of the digital distal-dorsal difference in the thermographic assessment of Raynaud\u2019s phenomenon. Microvasc Res 82:364\u2013368","journal-title":"Microvasc Res"},{"key":"4745_CR73","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/1744666X.2018.1464390","volume":"14","author":"JD Pauling","year":"2018","unstructured":"Pauling JD (2018) The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. Expert Rev Clin Immunol 14:431\u2013442","journal-title":"Expert Rev Clin Immunol"},{"key":"4745_CR74","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","volume":"42","author":"M Dziadzio","year":"1999","unstructured":"Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646\u20132655","journal-title":"Arthritis Rheum"},{"key":"4745_CR75","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","volume":"40","author":"B Coleiro","year":"2001","unstructured":"Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM (2001) Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40:1038\u20131043","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR76","first-page":"S103","volume":"30","author":"JD Pauling","year":"2012","unstructured":"Pauling JD, Shipley JA, Harris ND, McHugh NJ (2012) Use of infrared thermography as an endpoint in therapeutic trials of Raynaud\u2019s phenomenon and systemic sclerosis. Clin Exp Rheumatol 30:S103\u2013S115","journal-title":"Clin Exp Rheumatol"},{"key":"4745_CR77","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/art.40457","volume":"70","author":"JD Wilkinson","year":"2018","unstructured":"Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME, Britton J, Buch MH, del Galdo F, Denton CP, Dinsdale G, Griffiths B, Hall F, Howell K, MacDonald A, McHugh NJ, Manning JB, Pauling JD, Roberts C, Shipley JA, Herrick AL, Murray AK (2018) A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography. Arthritis Rheum 70:903\u2013911","journal-title":"Arthritis Rheum"},{"key":"4745_CR78","doi-asserted-by":"crossref","unstructured":"Daniels J, Pauling JD, Eccleston C (2018) Behaviour change interventions for the management of Raynaud\u2019s phenomenon: a systematic literature review. BMJ Open 2018;8:e024528","DOI":"10.1136\/bmjopen-2018-024528"},{"key":"4745_CR79","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"C Denton","year":"2016","unstructured":"Denton C, Hughes M, Gak N, Vila J, Buch MH, Chakravarty K et al (2016) BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford) 55:1906\u20131910","journal-title":"Rheumatology (Oxford)"},{"key":"4745_CR80","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2016","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2016) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"4745_CR81","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheum 70:1820\u20131828","journal-title":"Arthritis Rheum"},{"key":"4745_CR82","first-page":"CD000467","volume":"12","author":"F Rirash","year":"2017","unstructured":"Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA et al (2017) Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev 12:CD000467","journal-title":"Cochrane Database Syst Rev"},{"key":"4745_CR83","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","volume":"72","author":"M Roustit","year":"2013","unstructured":"Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski J-L (2013) Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 72:1696\u20131699","journal-title":"Ann Rheum Dis"},{"key":"4745_CR84","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/art.40242","volume":"69","author":"CP Denton","year":"2017","unstructured":"Denton CP, Hachulla \u00c9, Riemekasten G, Schwarting A, Frenoux J-M, Frey A, le Brun FO, Herrick AL, on behalf of the Raynaud Study Investigators (2017) Efficacy and safety of selexipag in adults with Raynaud\u2019s phenomenon secondary to systemic sclerosis. Arthritis Rheum 69:2370\u20132379","journal-title":"Arthritis Rheum"},{"key":"4745_CR85","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3899\/jrheum.150382","volume":"43","author":"P Moinzadeh","year":"2016","unstructured":"Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N, Melchers I, Mueller-Ladner U, Frerix M, Kreuter A, Tigges C, Lahner N, Susok L, Guenther C, Zeidler G, Pfeiffer C, Worm M, Karrer S, Aberer E, Bretterklieber A, Genth E, Simon JC, Distler JHW, Hein R, Schneider M, Seitz CS, Herink C, Steinbrink K, S\u00e1rdy M, Varga R, Mensing H, Mensing C, Lehmann P, Neeck G, Fiehn C, Weber M, Goebeler M, Burkhardt H, Buslau M, Ahmadi-Simab K, Himsel A, Juche A, Koetter I, Kuhn A, Sticherling M, Hellmich M, Kuhr K, Krieg T, Ehrchen J, Sunderkoetter C, Hunzelmann N, The German Network for Systemic Scleroderma (2016) Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. J Rheumatol 43:66\u201374","journal-title":"J Rheumatol"},{"key":"4745_CR86","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.semarthrit.2011.07.006","volume":"41","author":"ML Iorio","year":"2012","unstructured":"Iorio ML, Masden DL, Higgins JP (2012) Botulinum toxin a treatment of Raynaud\u2019s phenomenon: a review. Semin Arthritis Rheum 41:599\u2013603","journal-title":"Semin Arthritis Rheum"},{"key":"4745_CR87","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/micr.22379","volume":"35","author":"A Momeni","year":"2015","unstructured":"Momeni A, Sorice SC, Valenzuela A, Fiorentino DF, Chung L, Chang J (2015) Surgical treatment of systemic sclerosis-is it justified to offer peripheral sympathectomy earlier in the disease process? Microsurgery 35:441\u2013446","journal-title":"Microsurgery"},{"key":"4745_CR88","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/art.40123","volume":"69","author":"RJ Bello","year":"2017","unstructured":"Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD (2017) The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud\u2019s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheum 69:1661\u20131669","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04745-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04745-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T03:52:21Z","timestamp":1721620341000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04745-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":88,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4745"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04745-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Pauling has undertaken consultancy work and received speaker honoraria from Actelion pharmaceuticals. Dr Hughes has received speaker honoraria from Actelion pharmaceuticals. Dr Pope has undertaken consultancy work for AbbVie, Actelion, Baxter, Bayer, BMS, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}